These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16925504)

  • 1. InforMatrix: treatment of rheumatoid arthritis using biologicals.
    van den Bemt BJ; van den Hoogen FH; Breedveld FC; van der Tempel H; Janknegt R
    Expert Opin Pharmacother; 2006 Sep; 7(13):1769-89. PubMed ID: 16925504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. InforMatrix nucleoside/nucleotide reverse transcriptase inhibitor 'backbones'.
    Schreij G; Janknegt R
    Expert Opin Pharmacother; 2007 Oct; 8 Suppl 1():S37-47. PubMed ID: 17931077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding role of biologic agents in rheumatoid arthritis.
    Kalden JR
    J Rheumatol Suppl; 2002 Nov; 66():27-37. PubMed ID: 12435166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of biologicals in early rheumatoid arthritis.
    Haque UJ; Bathon JM
    Best Pract Res Clin Rheumatol; 2005 Feb; 19(1):179-89. PubMed ID: 15588978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. InforMatrix as an alternative tool in rational and transparent drug-decision making.
    Brenninkmeijer R; Mairs J; Timoney M; Scott M; McElnay J; Janknegt R
    Expert Opin Pharmacother; 2007 Oct; 8 Suppl 1():S31-6. PubMed ID: 17931076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological agents in rheumatoid arthritis.
    Weinblatt ME
    J Rheumatol Suppl; 1992 Jan; 32():85-8; discussion 88-91. PubMed ID: 1613738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are there special considerations relevant to trials of biologic agents?
    Strand V
    J Rheumatol Suppl; 1994 Sep; 41():41-5; discussion 45-9. PubMed ID: 7799384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A snapshot of immunotherapy for rheumatoid arthritis.
    Albani S
    Int Rev Immunol; 2006; 25(1-2):1-3. PubMed ID: 16669131
    [No Abstract]   [Full Text] [Related]  

  • 9. [Serious infection due to biologicals: risk only mildly elevated in patients with rheumatoid arthritis].
    den Broeder AA; Schers HJ
    Ned Tijdschr Geneeskd; 2015; 159():A9385. PubMed ID: 26271174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy.
    Caporali R; Conti F; Alivernini S; Atzeni F; Seriolo B; Cutolo M; Valesini G; Ferraccioli G; Sarzi-Puttini P; Salvarani C; Guiducci S; Zampogna G; Gremese E; Pipitone N; Scrivo R; Bugatti S; Montecucco C; Matucci-Cerinic M;
    Clin Exp Rheumatol; 2011; 29(3 Suppl 66):S7-14. PubMed ID: 21906423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.
    Siddiqui MA
    Curr Opin Rheumatol; 2007 May; 19(3):308-13. PubMed ID: 17414961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologicals and how they revolutionized rheumatology.
    Grisar J
    Wien Med Wochenschr; 2015 Jan; 165(1-2):1-2. PubMed ID: 25676698
    [No Abstract]   [Full Text] [Related]  

  • 13. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety.
    Favalli EG; Caporali R; Sinigaglia L; Pipitone N; Miniati I; Montecucco C; Matucci-Cerinic M;
    Clin Exp Rheumatol; 2011; 29(3 Suppl 66):S15-27. PubMed ID: 21906424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapies for treatment of rheumatoid arthritis.
    Piascik P
    J Am Pharm Assoc (Wash); 1997; NS37(1):14-6. PubMed ID: 9040165
    [No Abstract]   [Full Text] [Related]  

  • 16. Rheumatoid arthritis initial therapy: unanswered questions.
    O'Dell J
    J Rheumatol Suppl; 2005 Jan; 72():14-6. PubMed ID: 15660457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating biologic agents in rheumatoid arthritis: a framework for clinical trials.
    Strand V; Scott DL; Panayi GS
    J Rheumatol; 1994 Aug; 21(8):1390-2. PubMed ID: 7983635
    [No Abstract]   [Full Text] [Related]  

  • 18. Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: Implications for use of synovial sublining macrophages as a biomarker.
    Wijbrandts CA; Vergunst CE; Haringman JJ; Gerlag DM; Smeets TJ; Tak PP
    Arthritis Rheum; 2007 Nov; 56(11):3869-71. PubMed ID: 17968928
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination conventional DMARDs compared to biologicals: what is the evidence?
    Sethi MK; O'Dell JR
    Curr Opin Rheumatol; 2015 Mar; 27(2):183-8. PubMed ID: 25603037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rheumatoid arthritis: milestones in classification and treatment].
    Fiehn C
    Dtsch Med Wochenschr; 2011 Feb; 136(5):203-5. PubMed ID: 21271482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.